Document Detail


In situ hybridization in clinical pathology : Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer.
MedLine Citation:
PMID:  23052344     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The introduction of total genome sequencing led to the confirmation that tumors show substantial genetic heterogeneity. This phenomenon, which describes the presence of different genetic cell clones within a tumor also complicates the diagnostics of HER2. This article gives a review of new knowledge on polysomy 17 and genetic tumor heterogeneity in connection with HER2 determination of breast cancer.
Authors:
T Gaiser; J Rüschoff; R Moll
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  Der Pathologe     Volume:  -     ISSN:  1432-1963     ISO Abbreviation:  Pathologe     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006541     Medline TA:  Pathologe     Country:  -    
Other Details:
Languages:  GER     Pagination:  -     Citation Subset:  -    
Affiliation:
Institut für Pathologie, Universitätsklinikum Marburg, Marburg, Deutschland, timo.gaiser@umm.de.
Vernacular Title:
In-situ-Hybridisierung in der klinischen Pathologie : Bedeutung der Polysomie 17 für die HER2-Bestimmung und genetische Tumorheterogenität im Mammakarzinom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathogenesis of colitis-associated neoplasms.
Next Document:  Hereditary gastric cancer.